Kevin Ali

Kevin Ali was the CEO of Organon & Co., a global healthcare company focused on women's health and biosimilar products. Organon was established in June 2021 as a spinoff from Merck & Co. (known as MSD outside the United States and Canada). Information about current executives might have changed, so it is important to verify the latest information about the company.

Here are some key aspects of Kevin Ali's career:

1. Education: Kevin Ali holds a Bachelor of Science degree in Neuroscience from the University of Toronto and a Master of Business Administration degree from the Kellogg School of Management at Northwestern University.
2. Early career: Ali began his career in the pharmaceutical industry at Eli Lilly, where he held various roles in sales, marketing, and product development. He later joined Schering-Plough, which was eventually acquired by Merck & Co.
3. Merck & Co.: Kevin Ali has held several leadership positions at Merck & Co. over the years, with experience spanning across different regions and therapeutic areas. Prior to being appointed as the CEO of Organon, Ali served as the President of Emerging Markets for Merck's Human Health division, responsible for overseeing commercial operations in more than 140 countries.
4. CEO of Organon: In June 2021, Kevin Ali was appointed as the CEO of Organon & Co., following its spinoff from Merck & Co. Organon is focused on addressing unmet needs in women's health, with a portfolio of products across contraception, fertility, menopause, and hormonal health. The company is also involved in the development and commercialization of biosimilar products.
5. Leadership and strategy: As the CEO of Organon, Ali is responsible for shaping the company's vision, strategy, and growth plans. He is focused on leveraging the company's established product portfolio and pursuing new opportunities to address the unique healthcare needs of women across the globe.

It is essential to verify the current CEO and gather more recent information about the company, as my knowledge is based on data available up until September 2021.